Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05889845 · ClinicalTrials.gov registry record · Phase 3
Candin for the Treatment of Common Warts
A Phase 3 study of Common Warts (Verruca Vulgaris), sponsored by Nielsen BioSciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 18
- Study locations
NCT05889845: Completed Phase 3 study of Common Warts (Verruca Vulgaris), sponsored by Nielsen BioSciences.
NCT05889845 is a Phase 3 study of Common Warts (Verruca Vulgaris) that has completed, run by Nielsen BioSciences. The registered enrollment target is 330 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05889845, a Phase 3 study of Common Warts (Verruca Vulgaris), has completed, sponsored by Nielsen BioSciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 18
- Study locations
Study Summary
The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: * does treatment with Candin result in better clearance of warts than placebo * how many injections are required to result in wart clearance Participants will * have one wart selected for injection every two weeks until clearance * return 12 weeks after wart clearance for assessment of durability of response
Primary Outcome
Absence of visual or measurable wart maintained through the entire Observational Period for injected wart
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Candin, Intradermal Solution
Study Locations (18)
Arkansas
- Arkansas Pediatric Clinic - Bryant
- Johnson Dermatology - Fort Smith
- Dermatology Clinic of Arkansas - Hot Springs
California
- Velocity Clinical La Mesa - La Mesa
- Long Beach Research - Long Beach
- Integrative Skin Research - Sacramento
Texas
- DermResearch - Austin
- Austin Institute for Clinical Research - Pflugerville
Alabama
- Cahaba Dermatology - Birmingham
Colorado
- Velocity Clinical Englewood - Englewood
Illinois
- Kaminska Dermatology - Chicago
Massachusetts
- Integrated Dermatology of Newton-Brighton - Brighton
Michigan
- Hamzavi Dermatology - Fort Gratiot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2025-08-27 |
| Phase | Phase 3 |
What the finished NCT05889845 record still lists
NCT05889845 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Common Warts (Verruca Vulgaris) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05889845 lists 18 locations in 13 states (Arkansas, California, Texas).
Frequently Asked Questions
What is clinical trial NCT05889845 about?
NCT05889845 is a clinical study titled "Candin for the Treatment of Common Warts". The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: * does treatment with Candin result in bett...
What is the current status of trial NCT05889845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2025-01-22. Estimated completion is 2025-08-27.
What conditions does trial NCT05889845 study?
This clinical trial studies the following conditions: Common Warts (Verruca Vulgaris).
What interventions are being tested in trial NCT05889845?
The interventions under investigation include: Placebo (DRUG), Candin, Intradermal Solution (DRUG).
Who is sponsoring clinical trial NCT05889845?
This trial is sponsored by Nielsen BioSciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05889845 being conducted?
This trial has 18 study locations across Alabama, Arkansas, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Common Warts (Verruca Vulgaris)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05889845's enrollment target sits among peer trials
330 1066th of 2000 higher than 927 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI